About this article Cite this article Lin, A., Ding, Y., Li, Z
Abstract Objectives Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce the rates of major cardiovascular events, including myocardial infarction in people with type 2 diabetes, and decrease infarct size while preserving ventricular function in preclinical studies
6 This was associated with a significant increase in average population folate levels, and folate deficiency is now rare in Canada
While these drugs were initially used for the primary purpose of lowering blood glucose in people with type 2 diabetes, the satiety side effect and slower digestion also resulted in lower overall hunger, fewer cravings (particularly for fatty and sugary foods), and ultimately significant weight loss
It also stops your liver from dumping extra sugar into your bloodstream between meals
Quick Answer: Increased sweating is not listed as a recognized side effect in Zepbound's FDA-approved prescribing information